Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication).
RPCI, a wholly owned subsidiary of Ranbaxy Laboratories, sells and distributes generic prescription products in the Canadian healthcare system.
RPCI Canada president and general manager Paul Drake said the finished dosage form was developed, and will be manufactured within RLL’s Health Canada approved facilities located in India.
"We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," Drake added.